Crispr Therapeutics

Yahoo Finance • 10 days ago

Contrarius Global Equity Fund’s Thoughts on CRISPR Therapeutics’ (CRSP) Gene Editing Therapy

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here. The fund’s investor class returned 30.9% i... Full story

Yahoo Finance • 11 days ago

TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock

This article first appeared on GuruFocus. Cathie Wood's Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (NASDAQ:TSLA) and Rocket Lab (NASDAQ:RKLB). Selling activity focused o... Full story

Yahoo Finance • 11 days ago

Cathie Wood invests heavily in gene-editing companies, offloads $30 million worth Tesla stock

[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting holdings in... Full story

Yahoo Finance • 14 days ago

Cathie Wood Bets Big On Self-Driving and Gene-Editing Stocks Ahead of 2026

This article first appeared on GuruFocus. Cathie Wood's ARK Invest made additional portfolio adjustments, continuing moves seen in prior sessions. The firm increased holdings in WeRide Inc. (NASDAQ:WRD), a self-driving technology develop... Full story

Yahoo Finance • 16 days ago

Is CRISPR Therapeutics Stock Yesterday's News?

Key Points CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. 10 stocks we like better than CRISPR Therapeutics › CRIS... Full story

Yahoo Finance • 17 days ago

How Early Zugo-cel Data and Lilly Partnership Could Impact CRISPR Therapeutics (CRSP) Investors

Earlier this week, CRISPR Therapeutics reported encouraging early-stage clinical data for its allogeneic CD19 CAR T therapy, zugo-cel, in aggressive B-cell lymphoma and autoimmune diseases, and disclosed a new collaboration with Eli Lilly... Full story

Yahoo Finance • 18 days ago

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

CRISPR Therapeutics AG -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell do... Full story

Yahoo Finance • 22 days ago

2 Growth Stocks to Invest $1,000 in Right Now

Key Points A $1,000 investment can be an ideal amount to invest in an up-and-coming growth stock. The stocks below are still modest in size, with market capitalization of less than $6 billion. Such holdings come with risks, but they also... Full story

Yahoo Finance • 24 days ago

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Stanford researchers achieved complete diabetes reversal in mice using a combined blood stem cell and islet transplant that eliminates the ne... Full story

Yahoo Finance • 25 days ago

12 Days of Investing: My Top 12 Stocks to Buy Before 2026

Key Points There are only 12 investing days left in 2025. Now is a great time to load up on stocks that may win next year -- and over time. These 10 stocks could mint the next wave of millionaires › Soon, it will be countdown time, notin... Full story

Yahoo Finance • last month

uniQure N.V. (QURE): A Bear Case Theory

We came across a bearish thesis on uniQure N.V. on augur’s substack. In this article, we will summarize the bulls’ thesis on QURE. uniQure N.V.'s share was trading at $27.51 as of November 28th. QURE’s forward P/E was 27.93 according to Ya... Full story

Yahoo Finance • last month

Cathie Wood's Ark Invest weekly recap: Boosts AI and Crypto Bets, Trims Palantir, GitLab, and AMD

[Investment. Businessman using laptop and analyzing data with investment growth on stock markets, startups, real estate, technology, and financial trends on global network.] Harsa Maduranga/iStock via Getty Images Cathie Wood’s ARK Invest... Full story

Yahoo Finance • last month

What CRISPR Therapeutics’ (CRSP) Latest Trial Results Mean for Investors

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up roughly 3.8% of ARK Investment’s disclosed equity portfolio at third-quarter-end, with a position valued at approxima... Full story

Yahoo Finance • last month

Cathie Wood buys $56 million of megacap tech stock

Cathie Wood, head of Ark Investment Management, is best known for betting on early-stage tech names and high-growth innovators. But occasionally she makes a move into the megacap space when she sees value. That’s what Wood did in the past... Full story

Yahoo Finance • last month

Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50%

Key Points Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it’s one of her top holdings.10 stocks we like better than CRISPR Therapeutics... Full story

Yahoo Finance • last month

Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its Market Outperform rating and $86 price target for CRISPR Therapeutics AG (NASDAQ:CRSP) on November 11. The firm discus... Full story

Yahoo Finance • last month

Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the most oversold biotech stocks to invest in. Following the company’s third-quarter financial results, Oppenheimer reaffirmed its Outperform rating and $95 price target for CRISPR Therapeut... Full story

Yahoo Finance • 2 months ago

Cathie Wood's Ark Invest recap: pivots to AI drug discovery, gene editing stocks, reduces diagnostics and software exposure

[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello/Getty Images News During the last week, Cathie Wood’s ARK Invest reported strong buying in biotech, genomics, and deep-tech names acr... Full story

Yahoo Finance • 2 months ago

The Biotech Sector is Seeing a Major Boost From Programmable Cell Therapies in Chronic Disease Care

Issued on behalf of Avant Technologies Inc. VANCOUVER, British Columbia, Nov. 19, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – The autologous cell therapy market surpassed $10.1 billion in 2025 as biotechnology companies ra... Full story

Yahoo Finance • 2 months ago

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Key Points Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to the potential of their late-stage candidates, also could deliver a win for inve... Full story